Nivolumab
Radiotherapy
Fondazione Policlinico Universitario Agostino Gemelli IRCCSmonoclonal_antibodyPhase 4 / ApprovedActive
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 73/ 100
Competitive context
39 Active assets in the Radiotherapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 4 | B |
Toripalimab Northern Jiangsu People's Hospital | Phase 3 | B |
Eloxatin Tao Zhang | Phase 3 | B |
Capecitabine Tao Zhang | Phase 3 | B |
Axitinib Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 4 | B |
View all 42 →
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →